Selective Estrogen Receptor Degrader

What Selective Estrogen Receptor Degraders Are

Selective estrogen receptor degraders, often called SERDs, are a type of hormone therapy used mainly to treat breast cancers that have estrogen receptors (ER-positive). These receptors are proteins found inside some breast cancer cells that allow estrogen, a hormone, to attach and encourage cancer growth. SERDs work by binding to these estrogen receptors and causing them to break down, which helps block estrogen’s effects and can slow or stop the cancer from growing.

Examples of SERDs include fulvestrant (brand name Faslodex) and elacestrant (brand name Orserdu). These drugs are usually given when breast cancer has spread or when other hormone therapies have stopped working well.

Why SERDs Matter in Breast Cancer Treatment

Many breast cancers grow because they respond to estrogen. Treatments that block estrogen or lower its levels can help control these cancers. However, some cancers develop changes that make them less responsive to certain hormone therapies. SERDs are important because they not only block estrogen but also cause the estrogen receptors to be destroyed, which can be helpful when other treatments no longer work.

For example, elacestrant is approved for breast cancers that are estrogen receptor-positive, HER2-negative, and have a specific gene mutation called ESR1. It is used when the cancer has spread after other hormone treatments.

What Patients Might See or Hear About SERDs

If your doctor mentions SERDs, fulvestrant, or elacestrant, it may be part of your treatment plan for advanced breast cancer with certain features. You might see these drug names in your medical records, test results, or treatment discussions. Because these drugs have both generic and brand names, it can help to compare terms to avoid confusion.

It’s important to ask your care team how these drugs apply to your specific cancer and treatment history, what side effects to expect, and how they compare to other hormone therapies.

Where the Term SERD Might Appear

You may encounter the term selective estrogen receptor degrader or SERD in your treatment plan, medication list, clinical trial information, or lab reports describing your cancer’s hormone receptor status or gene mutations. Understanding this term in context can help you better follow your care and treatment options.

What SERD Does Not Automatically Mean

Seeing the term SERD or the name of a drug like elacestrant or fulvestrant does not mean a diagnosis or treatment decision has been made. These are treatment options for specific types of breast cancer and do not apply to all breast cancers or other cancers unless your doctor says so. Always discuss with your care team what these terms mean for your care.

Common Questions to Ask Your Care Team

You might want to ask why a SERD is recommended for you, how it works, what side effects you might experience, and how it compares to other hormone therapies. Also, ask how your cancer’s specific features, like ESR1 mutations, affect treatment choices and what monitoring will be done during therapy.

How to Read the Term in Context

Selective estrogen receptor degrader is one part of a complex treatment plan. It’s important to understand it as a medicine that targets estrogen receptors in certain breast cancers, not as a diagnosis or a guarantee of results. Discussing your individual case with your healthcare team will help you understand how this treatment fits your situation.

Safety and Next Steps

This information is educational and cannot decide what is safe or appropriate for any individual. If you see the term SERD or a drug name like elacestrant or fulvestrant in your medical records or treatment plan, the best next step is to ask your care team what it means for you personally. They can explain how this treatment fits your cancer type, stage, and overall care plan.